▲ +66.01% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Aeglea BioTherapeutics in the last 3 months. The average price target is $12.67, with a high forecast of $15.00 and a low forecast of $11.00. The average price target represents a 66.01% upside from the last price of $7.63.
The current consensus among 4 polled investment analysts is to buy stock in Aeglea BioTherapeutics. This Buy consensus rating has held steady for over two years.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.